Post-covid syndrome, possibilities for therapy of asthenic disorders with Selank

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Post-COVID syndrome develops after a COVID-19 infection, and is also observed in cases of mild or asymptomatic course of the disease. The most common symptoms of bridge syndrome are asthenia and decreased performance, with further development of cognitive deficit. Taking into account the leading role of immune disorders in the pathogenesis of COVID-19, the use of immunotropic drugs that have both direct activity in relation to immune interactions and those that work indirectly through the reduction of post-stress reactions that can maintain immune dysfunction seems promising. In this regard, Selank is of interest, a peptide created on the basis of the immune regulator tafcin, which has proven itself well in the treatment of a wide range of neurotic and neurosis–like disorders.

Objective. To study the efficacy of the drug Selank in patients with complaints of asthenia, decreased performance and emotional disorders that developed after COVID-19 infection.

Material and methods. The study included 64 patients divided into 2 groups: Group 1 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) and the drug Selank; Group 2 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) without the drug Selank.

Results. The drug Selank (nasal drops, 1.5 mg) when used at a dose of 2-3 drops 4 times a day for 30 days showed a good effect in patients with asthenia and impaired mental performance. In parallel, relief of anxiety and depressive symptoms was observed. Based on the data obtained, it can be argued that Selank demonstrates a good effect when used in patients with asthenia, which developed as a result of a previous COVID-19 viral infection, with concomitant depressive and anxiety symptoms.

Full Text

Restricted Access

About the authors

М. G. Pogodina

Kuban State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: m.g.pogodina@mail.ru
Russian Federation, Krasnodar

Е. Nikiforova

Kuban State Medical University, Ministry of Health of Russia

Email: m.g.pogodina@mail.ru
Russian Federation, Krasnodar

References

  1. Андреева Л.А., Мезенцева М.В., Наровлянский А.Н. и др. Перспективы создания новых пептидных лекарственных препаратов, обладающих противоинфекционной и иммуномодулирующей активностью. Инфекция и иммунитет. 2011; 1 (2): 171–6 [Andreeva L.A., Mezentseva M.V., Narovlianskiy A.N. et al. The perspectives of development of new peptide preparations for clinical use which have anti-infection and immune-modulating activity. Infekc immun. 2011; 1 (2): 171–6 (in Russ.)].
  2. Белоглазов В.А., Вербенко В.А., Лугачев Б.И. Применение интраназального препарата Селанк 0,15% с целью психофармакологической коррекции в комплексной терапии пациентов с бронхиальной астмой. Поликлиника. 2019; 3: 34–8 [Beloglazov V.A., Verbenko V.A., Lugachov B.I. The use of intranasal drug Selank 0,15% for the purpose of psychopharmacological correction in the treatment of patients with bronchial asthma. Poliklinika. 2019; 3: 34–8 (in Russ.)].
  3. Вербенко В.А., Шакина Т.А. Новые возможности потенцирования действия селективных ингибиторов обратного захвата серотонина регуляторным пептидом Селанк при терапии тревожно-депрессивных расстройств. Врач. 2019; 30 (10): 76–81 [Verbenko V., Shakina T. New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders. Vrach. 2019; 30 (10): 76–81 (in Russ.)]. doi: 10.29296/25877305-2019-10-16
  4. Особенности анксиолитического и стрессопротективного действия пептидного препарата Селанк® при терапии расстройств адаптации и посттравматического стрессового расстройства. Медицинский алфавит. 2017; 3 (32): 21–6 [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.)].
  5. Вербенко В.А., Федоров В.Н. Оптимизация терапии тревожных расстройств. Таврический журнал психиатрии. 2016; 20 (3): 5–14 [Verbenko V.A., Fedorov V.N. Optimization of therapy for anxiety disorders. Tauride Journal of Psychiatry. 2016; 20 (3): 5–14 (in Russ.)].
  6. Высоков И.Е. Математические методы в психологии: учебник и практикум для вузов. 3-е изд., перераб. и доп. М.: Издательство Юрайт, 2024 [Vysokov I.E. Mathematical methods in psychology: textbook and workshop for universities. 3rd ed., revised. and add. M.: Yurayt Publishing House, 2024 (in Russ.)].
  7. Захаров В.В., Громова Д.О., Эдильгиреева Л.А. и др. Когнитивные и астенические расстройства после COVID-19. РМЖ. 2022; 4: 15–9 [Zakharov V.V., Gromova D.O., Edilgireeva L.A. et al. Cognitive and asthenic disorders after COVID-19. RMJ. 2022; 4: 15–9 (in Russ.)].
  8. Зозуля Ф.Ф., Незнамов Г.Г., Сюняков Т.С. и др. Эффективность и возможные механизмы действия нового анксиолитика селанка при терапии генерализованного тревожного расстройства и неврастении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008; 108 (4): 38–48 [Zozulia A.A., Neznamov G.G., Siuniakov T.S. et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2008; 108 (4): 38–48 (in Russ.)].
  9. Зуева И.Б., Ким Ю.В., Суслова М.Ю. Постинфекционная астения у пациентов, перенесших COVID-19 на амбулаторном этапе. Международный журнал сердца и сосудистых заболеваний. 2022; 10 (33.1): 18–20 [Zueva I.B., Kim Yu.V., Suslova M.Yu. Post-viral asthenia in patients with COVID-19 who received outpatient care. International Heart and Vascular Disease Journal. 2022; 10 (33.1): 24–30 (in Russ.)]. doi: 10.24412/2311-1623-2022-33.1-24-30
  10. Кобзарь А.И. Прикладная математическая статистика. М.: Физматлит, 2006; с. 626–8 [Kobzar A.I. Applied mathematical statistics. M.: Fizmatlit, 2006; рр. 626–8 (in Russ.)].
  11. Компьютерная психологическая диагностика. Электронный ресурс [Computerized psychological diagnostics. Electronic resource (in Russ.)]. URL: https://cpd-program.ru/methods.html
  12. Королева С.В., Мясоедов Н.Ф. Физиологические эффекты Селанка и его фрагментов. Известия РАН. Серия биологическая. 2019; 4: 429–38 [Koroleva S.V., Mjasoedov N.F. Physiological Effects of the Selank and Its Fragments. Proceedings of the Russian Academy of Sciences. Biological Series. 2019; 4: 429–38 (in Russ.)]. doi: 10.1134/S0002332919040076
  13. Косенко В.Г., Никифорова Е.Ю., Погодина М.Г. и др. Особенности психологических защит в период пандемии COVID-19. Психическое здоровье. 2022; 17 (3): 19–26 [Kosenko V.G., Nikiforova E.YU., Pogodina M.G. et al. Features of psychological defenses during the COVID-19 pandemic. Mental Health. 2022; 17 (3): 19–26 (in Russ.)]. doi: 10.25557/2074-014X.2022.03.19-26
  14. Медведев В.Э. Терещенко О.Н., Кост Н.В. и др. Оптимизация терапии тревожных расстройств пептидным препаратом Селанк. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115 (6): 33–40 [Medvedev V.E., Tereshchenko O.N., Kost N.V. et al. Optimization of the treatment of anxiety disorders with selank. S.S. Korsakov Journal of Neurology and Psychiatry. 2015; 115 (6): 33–40 (in Russ.)]. doi: 10.17116/jnevro20151156133-40
  15. Опросник выраженности психопатологической симптоматики. Электронный ресурс [Questionnaire of the expression of psychopathologic symptomatology. Electronic resource (in Russ.)]. URL: https://studfile.net/preview/3535528/page:5/
  16. Редько А.Н., Косенко В.Г., Косенко Н.А. и др. Социодемографические и клинические особенности у лиц с психическими расстройствами, обращающихся в негосударственные медицинские учреждения в период пандемии COVID-19 и первого года ее течения (2019-2020). Социальная и клиническая психиатрия. 2022; 32 (1): 74–81 [Redko A.N., Kosenko V.G., Kosenko N.A. et al. Sociodemographic and clinical features of persons with mental disorders who apply to non-governmental medical institutions in the period before the COVID-19 pandemic and the first year of its course (2019-2020). Social and clinical psychiatry. 2022; 32 (1): 74–81 (in Russ.)].
  17. Скребицкий В.Г., Шаронова И.Н. Технологии изучения механизмов действия препаратов для коррекции когнитивных расстройств. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2018; 2: 10–20 [Skrebitsky V.G., Sharonova I.N. Technologies of studying the mechanisms of action of drugs for the correction of cognitive disorders. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders. 2018; 2: 10-20 (in Russ.)]. doi: 10.24411/2071-5315-2018-12025
  18. Солдаткин В.А., Ковалев А.И., Крючкова М.Н. и др. Клиническая психометрика: учебное пособие. Ростов-на-Дону: Изд-во РостГМУ, 2020; с. 80–7 [Soldatkin V.A., Kovalev A.I., Kryuchkova M.N. et al. Clinical psychometrics: textbook. Rostov-on-Don: Rostov State Medical University Publishing House, 2020; рр. 80–7 (in Russ.)]..
  19. Соллертинская Т.Н., Шорохов М.В., Мясоедов Н.Ф. и др. Пептидные биорегуляторы семакс и селанк в компенсации нарушенных когнитивных функций и межполушарной асимметрии у приматов. Асимметрия. 2014; 8 (4): 53–65 [Sollertinskaja T.N., Shorokhov M.V., Myasoedov N.F. et al. The peptide bioregulators semax and selank in cognitive function disturbance compensation and brain interhemispheric asymmetry in primates. Journal of asymmetry. 2014; 8 (4): 53–65 (in Russ.)].
  20. Субъективная шкала оценки астении. Электронный ресурс [Subjective assessment scale for asthenia. Electronic resource (in Russ.)]. URL: https://ra-kurs-sochi.ru/ekspress-test#gallery-2
  21. Танашян М.М., Раскуражев А.А., Кузнецова П.И. и др. Перспективы и возможности терапии пациентов с астеническим синдромом после перенесенной новой коронавирусной инфекции COVID-19. Терапевтический архив. 2022; 94 (11): 1285–93 [Tanashyan M.M., Raskurazhev A.A., Kuznetsova P.I. et al. Prospects and possibilities for the treatment of patients with long COVID-19 syndrome. Terapevticheskii Arkhiv. 2022; 94 (11): 1285–93 (in Russ.)]. doi: 10.26442/00403660.2022.11.201981
  22. Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения. Неврология, нейропсихиатрия, психосоматика. 2021; 13 (3): 93–8 [Khasanova D.R., Zhitkova Yu.V., Vaskaeva G.R. Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (3): 93–8 (in Russ.)]. doi: 10.14412/2074-2711-2021-3-93-98
  23. Тафтсин, Селанк и аналоги. Иммунитет, антистресс, либидо [Tuftsin, Selank and analogs. Immunity, anti-stress, libido (in Russ.)]. URL: https://russianpeptide.com/taftsin-selank-i-analogi-immunitet-antistress-libido/
  24. Ясенявская А.Л., Самотруева М.А., Башкина О.А. и др. Нейропептидная регуляция иммунитета. Иммунология. 2018; 39 (5-6): 326–36 [Yasenyavskaya A.L., Samotrueva M.A., Bashkina O.A. et al. Neuropeptide regulation of immunity. Immunologiya. 2018; 39 (5-6): 326–36 (in Russ.)]. doi: 10.18821/0206-4952-2018-39-5-6-326-336
  25. Alemanno F., Houdayer E., Parma A. et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID rehabilitation unit experience. PLoS One. 2021; 16: e0246590. doi: 10.1371/journal.pone.0246590
  26. Ali Awan H., Najmuddin Diwan M., Aamir A. et al. SARS-CoV-2 and the Brain: What Do We Know about the Causality of «Cognitive COVID». J Clin Med. 2021; 10 (15): 3441. doi: 10.3390/jcm10153441
  27. Almeria M., Cejudo J.C., Sotoca J. et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020; 9: 100163. doi: 10.1016/j.bbih.2020.100163
  28. Amenta E.M., Spallone A., Rodriguez Barradas M.C. et al. Post-acute COVID-19: An overview and approach to classification. Open Forum Infect Dis. 2020; 7 (12): ofaa509. doi: 10.1093/ofid/ofaa509
  29. Baig A., Khaleeq A., Ali U. et al. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution. Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosc. 2020; 11 (7): 995–8. doi: 10.1021/acschemneuro.0c00122
  30. Berlit P., Frölich L., Förstl H. The «Fourth Wave»? COVID-19 and consecutive cognitive impairment. Dtsch Med Wochenschr. 2021; 146 (10): 671–6. doi: 10.1055/a-1468-1529
  31. Bradburn S., Sarginson J., Murgatroyd C.A. Association of Peripheral Interleukin-6 with Global Cognitive Decline in Non-demented Adults: A Meta-Analysis of Prospective Studies. Front Aging Neurosci. 2018; 9: 438. doi: 10.3389/fnagi.2017.00438
  32. Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai et al. The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020; 12 (1): 86. doi: 10.1186/s13195-020-00652-z
  33. Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing Long COVID in an International Cohort:7 Months of Symptoms and Their Impact. medRxiv preprint. doi: 10.1101/2020.12.24.20248802. URL: https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v3
  34. Goеrtz Y.M.J., van Herck M., Delbressine J.M. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the postCOVID-19 syndrome? ERJ Open Res. 2020; 6 (4): 00542-2020. doi: 10.1183/23120541.00542-2020
  35. Greenhalgh T., Knight M., A’Court M. et al. Management of post-acute COVID-19 in primary care. BMJ. 2020; 370: m3026. doi: 10.1136/bmj.m3026
  36. Hakamata Y., Suzuki Y,, Kobashikawa H. et al. Neurobiology of early life adversity: A systematic review of meta-analyses towards an integrative account of its neurobiological trajectories to mental disorders. Front Neuroendocrinol. 2022; 65: 100994. doi: 10.1016/j.yfrne.2022.100994
  37. Haijing Ma, Jiatong Xu, Ruonan Li et al. The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis. Front Psychiatry. 2022; 13: 844176. doi: 10.3389/fpsyt.2022.844176
  38. Halpin S.J., McIvor C., Whyatt E.G. et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021; 93: 1013–22. doi: 10.1002/jmv.26368
  39. Helms J., Kremer S., Merdji H. et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020; 382 (23): 2268–70. doi: 10.1056/NEJMc2008597
  40. Jaywant A., Vanderlind W.M., Alexopoulos G.S. et al. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. 2021; 10: 1–6. doi: 10.1038/s41386-021-00978-8
  41. Maltezou H.C., Pavli A., Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021; 9 (5): 497. doi: 10.3390/vaccines9050497
  42. Maltezou H.C., Raftopoulos V., Vorou R. et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. 2021; 223 (7): 1132–8. doi: 10.1093/infdis/jiaa804
  43. Mazza M.G., Palladini M., De Lorenzo R. et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun Health. 2021; 94: 138–47. doi: 10.1016/j.bbi.2021.02.021
  44. Mendez R., Balanza-Martinez V., Luperdi S.C. et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021; 290 (3): 621–31. doi: 10.1111/joim.13262
  45. Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15. doi: 10.1038/s41591-021-01283-z
  46. Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021; 52 (6): 575–81. doi: 10.1016/j.arcmed.2021.03.010
  47. Pilotto A., Cristillo V., Cotti Piccinelli S. et al. COVID-19 severity impacts on long-term neurological manifestation after hospitalisation. medRxiv preprint. doi: 10.1101/2020.12.27.20248903. URL: https://www.medrxiv.org/content/10.1101/2020.12.27.20248903v1.full.pdf
  48. Ritchie K., Chan D., Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage? Brain Commun. 2020; 2 (2): fcaa069. doi: 10.1093/braincomms/fcaa069
  49. Rogers J.P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7 (7): 611–27. doi: 10.1016/S2215-0366(20)30203-0
  50. Stefano G.B., Büttiker P., Weissenberger S. et al. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis. Med Sci Monit. 2021; 27: e933015. doi: 10.12659/MSM.933015
  51. Shih-Jen Tsai. Role of interleukin 8 in depression and other psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 106: 110173. doi: 10.1016/j.pnpbp.2020.110173
  52. Tayebati S.K., Amenta F., Tomassoni D. Cerebrovascular and blood-brain barrier morphology in spontaneously hypertensive rats: effect of treatment with choline alphoscerate. CNS Neurol Disord Drug Targets. 2015; 14 (3): 421–9. doi: 10.2174/1871527314666150225140855
  53. Traini E., Bramanti V., Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013; 10 (10): 1070–9. doi: 10.2174/15672050113106660173
  54. Wijeratne T., Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020; 419: 117179. doi: 10.1016/j.jns.2020.117179
  55. Yuan Zhang, Jingjing Wang, Yu Ye et al. Peripheral cytokine levels across psychiatric disorders: A systematic review and network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023; 125: 110740. doi: 10.1016/j.pnpbp.2023.110740

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies